Company Overview | Summary

Garnet BioTherapeutics is a Clinical Stage, venture-backed cell therapy company focused on dermal-based regenerative therapy. The Company has what we believe to be a unique opportunity due to:

Largely Solved Commercial Manufacturing Scale-up
    • Ability to generate high-volume (estimated in billions) of doses        derived from a single adult bone marrow donor;

Proprietary Cells Designed With “Locked-In” Function
    • The cells used for these lead indications, and produced in        Garnet BioTherapeutics’ proprietary process will not become        unwanted tissue types when administered clinically;

Regulatory Pathway More Clear
    • lower risk pathway due to predictable performance and        pharmacodynamics of GBT 009;
 
Clinical Stage
    • Past clinical trial performed in post MI patients;
    • Infusion through cardiac catheterization into the heart;
       cell counts in the millions infused; well tolerated.